新诊断射血分数降低心衰:指南推荐药物治疗的时机、顺序与滴定
TITRATE-HF研究在48家荷兰医院的前瞻性注册中纳入1508例新诊断HFrEF患者,记录从诊断至6个月的GRMT启动、调整与停药。6周时46%使用四联疗法,6个月时66.3%使用四联疗法但仅1.3%达到全部四类药物目标剂量;结论认为快速启动GRMT可行,但需积极持续滴定。
要点
- 新诊断HFrEF患者6个月时仅66.3%使用四联疗法,1.3%达四药目标剂量。
- 目标剂量未达到的原因中,20%-37%为副作用,很大部分为医生接受次优剂量。
- 药物滴定在诊断后60天内频繁,之后减少;再挑战停药药物成功率超过83%。
核心结论
- TITRATE-HF研究表明在真实临床实践中快速启动HFrEF的GRMT是可行的。
- 结果强调需要在最初几个月之后仍采取积极方法和持续剂量滴定以充分优化治疗。
研究设计与样本
- TITRATE-HF研究为正在进行的在48家荷兰医院开展的前瞻性心衰注册研究。
- 本分析聚焦新诊断HFrEF患者,记录每种GRMT药物从诊断至6个月的启动、剂量调整、停药及原因。
- 共纳入1508例新诊断HFrEF患者,中位年龄70岁(IQR 62-77),女性31%,中位左心室射血分数30%(IQR 25-35)。
主要发现
- 6周时46%的患者使用四联疗法。
- 诊断后6周内50%的患者曾在某一时点处方四联疗法,其中84%在180天后仍维持。
- 6个月时66.3%的患者处方四联疗法,但仅1.3%达到全部四类药物目标剂量。
- 目标剂量未达到的病例中20%-37%归因于副作用,很大部分归因于医生接受次优剂量。
- 药物滴定在诊断后60天内频繁,之后减少;ACEI、ARB、ARNI、β受体阻滞剂、MRA和SGLT2i的停药率分别为13%、11%、9%、9%、11%和9%,主要因副作用或不耐受。
临床怎么用
- 对新诊断HFrEF患者可快速启动GRMT,但需在最初几个月后持续主动滴定剂量。
- 应关注医生接受次优剂量这一可干预障碍,而非仅归因于副作用。
- 对因副作用或不耐受停用的GRMT药物,再挑战成功率超过83%,可考虑重新尝试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Despite guidelines recommending rapid initiation and up-titration of Guideline-recommended medical therapy (GRMT) for heart failure (HF) with reduced ejection fraction (HFrEF), its feasibility in daily practice remains unclear. TITRATE-HF studies the feasibility of rapid GRMT implementation in de novo HFrEF patients, investigating titration patterns and identifying barriers to effective treatment. METHODS: This analysis focuses on the de novo HFrEF patients included in the TITRATE-HF study, an ongoing prospective HF registry conducted in 48 Dutch hospitals. A detailed logbook for each GRMT drug class was recorded, from diagnosis to six months, including initiations, dose adjustments, discontinuations, and reasons for changes. RESULTS: The study included 1508 de novo HFrEF patients (median age: 70 years [inter-quartile ranges, IQR 62-77]; 31% women; median left ventricular ejection fraction: 30% [IQR 25-35]). At 6 weeks, 46% of patients were using quadruple therapy. Within 6 weeks post-HFrEF diagnosis, 50% of patients were prescribed quadruple therapy at some point, with 84% remaining on it after 180 days. At 6 months, 66.3% of patients were prescribed quadruple therapy, but only 1.3% achieved target doses for all four drug classes. While side effects accounted for 20%-37% of cases where target doses were not reached, a large proportion was attributed to physicians accepting suboptimal doses. Drug titrations occurred frequently in the first 60 days after diagnosis, fading afterwards. Discontinuation rates for angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, angiotensin receptor-neprilysin inhibitors, beta-blocker, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors were 13%, 11%, 9%, 9%, 11%, and 9%, respectively, primarily due to side effects or intolerances. Rechallenging these drug classes was successful in over 83% of patients. CONCLUSIONS: The TITRATE-HF study demonstrates that rapid initiation of GRMT for HFrEF is feasible in real-world clinical practice. Nonetheless, our results highlight the urgency for a proactive approach and ongoing dose titration of pharmacological therapy beyond the initial first months to fully optimize treatment.
引用
- Malgie, Wilde, Brunner-La Rocca, et al. Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy. Eur Heart J. 2025. PMID: 40272103. doi:10.1093/eurheartj/ehaf244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。